Abstract:Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor. Prognosis is poor and survival is low in patients diagnosed with this disease, with a survival rate of ~12% at 5 years. Immunotherapy, including adoptive T cell transfer therapy, has not impacted the outcomes in patients with PDAC, due in part to the hostile tumor microenvironment (TME) which limits T cell trafficking and persistence. We posit that murine models serve as useful tools to study the fate of T cell therapy. Currently, genetically engineered mouse models (GEMMs) for PDAC are considered a “gold-standard” as they recapitulate many aspects of human disease. However, these models have limitations, including marked tumor variability across individual mice and the cost of colony maintenance. Methods Using flow cytometry and immunohistochemistry, we characterized the immunological features and trafficking patterns of adoptively transferred T cells in orthotopic PDAC (C57BL/6) models using two mouse cell lines, KPC-Luc and MT-5, isolated from C57BL/6 KPC-GEMM (Kras LSL-G12D/+ p53 −/− and Kras LSL-G12D/+ p53 LSL-R172H/+ , respectively). Results The MT-5 orthotopic model best recapitulates the cellular and stromal features of the TME in the PDAC GEMM. In contrast, far more host immune cells infiltrate the KPC-Luc tumors, which have less stroma, although CD4 + and CD8 + T cells were similarly detected in the MT-5 tumors compared with KPC-GEMM in mice. Interestingly, we found that chimeric antigen receptor (CAR) T cells redirected to recognize mesothelin on these tumors that signal via CD3ζ and 41BB (Meso-41BBζ-CAR T cells) infiltrated the tumors of mice bearing stroma-devoid KPC-Luc orthotopic tumors, but not MT-5 tumors. Conclusions Our data establish for the first time a reproducible and realistic clinical system useful for modeling stroma-rich and stroma-devoid PDAC tumors. These models shall serve an indepth study of how to overcome barriers that limit antitumor activity of adoptively transferred T cells.

Animal models for modeling pancreatic cancer and novel drug discovery

Patient-derived Xenograft Models in Hepatopancreatobiliary Cancer

Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology

Research progress in the establishment of pancreatic cancer models and preclinical applications

Advancements in Preclinical Models of Pancreatic Cancer

Progress in models of pancreatic cancer

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Modelling the micro- and macro- environment of pancreatic cancer: from patients to pre-clinical models and back

Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models

Animal models of pancreatic ductal adenocarcinoma

Identifying the Morphological and Molecular Features of a Cell-Based Orthotopic Pancreatic Cancer Mouse Model during Growth over Time

Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens

Emerging In Vitro and In Vivo Models: Hope for the Better Understanding of Cancer Progression and Treatment

Orthotopic and metastatic tumour models in preclinical cancer research

Experimental mouse models for translational human cancer research

K-ras-driven Engineered Mouse Models for Pancreatic Cancer.

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy

Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo

Targeted irradiation in an autochthonous mouse model of pancreatic cancer

The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer